China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an area deprioritized by big pharma.

While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.

Japanese firm backs off potential acquisition of Australian cell therapy venture after the two sides fail to agree on deal terms.